
Sign up to save your podcasts
Or
FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide.
Featuring: Sara Heath, executive editor, Xtelligent Healthcare
Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent Healthcare
In today’s episode, we’ll cover…
and more!
References:
To learn more about GLP-1s, check out our Pharma Life Sciences and Patient Engagement sites.
4.7
3434 ratings
FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide.
Featuring: Sara Heath, executive editor, Xtelligent Healthcare
Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent Healthcare
In today’s episode, we’ll cover…
and more!
References:
To learn more about GLP-1s, check out our Pharma Life Sciences and Patient Engagement sites.
1,650 Listeners
177 Listeners
32,299 Listeners
43,483 Listeners
56,285 Listeners
478 Listeners
9,190 Listeners
171 Listeners
184 Listeners
1,134 Listeners
2,969 Listeners
391 Listeners
618 Listeners
9,236 Listeners
54 Listeners